
Androlabs has received UK marketing authorisation for a new presentation of Testavan 4.6 mg/actuation transdermal gel for testosterone replacement therapy …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

